Genomic spectra of biliary tract cancer

By Hiromi Nakamura, Y. Arai, Y. Totoki, T. Shirota, Asmaa Elzawahry, Mamoru Kato, Natsuko Hama, F. Hosoda, Tomoko Urushidate, Shoko Ohashi and 7 more. Nature Genetics, 2015

1,159 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/190caeccfaef7f8cc86d9940e464aa25f48ed1aa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. G. Gores

In Pathology and Forensic Medicine

1. Alejandro Forner1 , 2
2. Jordi Bruix1 , 2
3. J. Llovet

In Surgery

1. Sumera I. Ilyas
2. Jordi Bruix1 , 2
3. G. Gores

Citations in the corpus

• Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma (2017, methodology): “We integrated (i) 71 WGS CCAs, (ii) 188 targeted-sequenced CCAs (Supplementary Table 5), and (iii) 200 exome-sequenced CCA (8), and performed gene significance analyses using MutSigCV (58) and IntOGen (59).”
• Cholangiocarcinoma 2020: the next horizon in mechanisms and management (2020, positive): “By contrast, large bile duct iCCA, similar to pCCA and dCCA, shows a high frequency of mutations in KRAS and/or TP53 genes 51,53,56,57 .”
• Cholangiocarcinoma — evolving concepts and therapeutic strategies (2017, positive): “Activating mutations of the proto­oncogene KRAS are a frequent occurrence (11–25%, depending on dis­ ease subtype) in cholangiocarcinomas 92,95,101 , and are associated with unfavourable progression­free sur­ vival (PFS) and overall survival 95,102,113 .”